Nocturia — Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033
Nocturia is a condition where an individual wakes up more than once during the night to urinate. It is divided into two main categories: upper urinary tract and lower urinary tract dysfunction. Nocturia is often associated with lower urinary tract symptoms (LUTS), such as benign prostatic obstruction (BPO) and overactive bladder (OAB). However, it can also be caused by nighttime urine overproduction or nocturnal polyuria (NP), resulting from renal, cardiovascular, or pulmonary factors. Nocturia is multifactorial and can be caused by one of four main problems:
- Nocturnal polyuria
- Global polyuria
- Bladder functional storage issues
- Sleep disorders
Hormonal problems are primarily responsible for nocturnal and global polyuria. The management of nocturia requires multidisciplinary care, and treatment involves behavioral interventions and medications, including anticholinergics.
- It affects 50 million people in the United States, with 10 million diagnosed with nocturia but only 1.5 million receiving specific therapy for it.
- Approximately 33% of adults aged 30 and above experience the need to visit the bathroom at least twice during the night, and approximately 70% of these individuals are bothered by this.
- About 50% of all adults over the age of 65 get up at least once a night to void, and approximately 24% experience two or more episodes of nocturia per night.
Thelansis’s “Nocturia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Nocturia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Nocturia across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Nocturia Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
